Vera Therapeutics (NASDAQ:VERA) Issues Quarterly Earnings Results

Vera Therapeutics (NASDAQ:VERA) announced its quarterly earnings data on Thursday. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.32, FiscalAI reports. The firm had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million.

Here are the key takeaways from Vera Therapeutics’ conference call:

• TRUTAKNA showed strong kidney-function results in ORIGIN 3: At 104 weeks, it reduced the risk of kidney disease progression by 76% versus placebo, with kidney-function decline near a physiologic rate. Vera submitted an FDA application seeking full approval and plans an EU application in the first quarter of 2027.
• The early U.S. launch generated about 700 Patient Start Forms since the July approval, and third-quarter product revenue was $10.3 million; management said roughly half the revenue reflected demand and half inventory. The company said prescriptions span patients with both higher and lower proteinuria, while acknowledging that adoption is still at an early stage.
• Interim PIONEER results showed a 52% reduction in proteinuria from baseline at week 24 among 101 adults across broader IgA nephropathy cohorts, including patients with lower kidney function. Results in primary membranous nephropathy were preliminary, based on 16 patients.
• Spending and cash use increased as Vera funded commercialization: third-quarter net loss was $93.7 million, and operating cash use totaled $305.9 million for the first nine months of 2026. The company reported $384 million in cash and marketable securities at quarter-end and borrowed $75 million in October; additional debt capacity is subject to conditions.

Vera Therapeutics Price Performance

Shares of VERA stock traded down $1.83 during mid-day trading on Thursday, hitting $30.14. 1,419,234 shares of the stock were exchanged, compared to its average volume of 1,622,788. The firm has a fifty day moving average of $31.83 and a 200 day moving average of $36.84. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics has a 52-week low of $23.05 and a 52-week high of $56.05. The company has a market cap of $2.17 billion, a PE ratio of -5.14 and a beta of 1.07.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. JPMorgan Chase & Co. lifted their price objective on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, September 8th. HC Wainwright dropped their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $76.86.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. This represents a 7.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.